Also known as: CMMI
More than 30 approved cell and gene therapies carry prices from nearly $1 million to over $4 million, creating fiscal pressure for Medicaid. A federal access model launched in 2024 aims to centralize outcomes-based contracting.
Sixteen pharmaceutical companies have voluntarily agreed to Most Favored Nation pricing covering 70% of Medicare drug spending, while industry leaders warn of China's growing competitiveness in drug development and clinical trials.
The Trump administration's pharmaceutical deals and TrumpRx program claim to lower drug prices, but analysis reveals limited savings, pre-existing investments, and weakened Medicare negotiation provisions that may cost billions.
